KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.87 $1.65 Friday, 26th Apr 2024 ADAP stock ended at $1.08. This is 1.42% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.83% from a day low at $1.03 to a day high of $1.09.
90 days $0.730 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Mar 04, 2016 $8.24 $8.24 $8.24 $8.24 176 000
Mar 03, 2016 $8.33 $8.33 $8.33 $8.33 137 300
Mar 02, 2016 $8.38 $8.38 $8.38 $8.38 132 300
Mar 01, 2016 $7.45 $7.45 $7.45 $7.45 145 200
Feb 29, 2016 $7.19 $7.19 $7.19 $7.19 128 600
Feb 26, 2016 $7.82 $7.82 $7.82 $7.82 163 700
Feb 25, 2016 $7.67 $7.67 $7.67 $7.67 368 300
Feb 24, 2016 $7.38 $7.38 $7.38 $7.38 157 000
Feb 23, 2016 $7.63 $7.63 $7.63 $7.63 100 100
Feb 22, 2016 $8.39 $8.39 $8.39 $8.39 95 900
Feb 19, 2016 $8.22 $8.22 $8.22 $8.22 98 800
Feb 18, 2016 $8.27 $8.27 $8.27 $8.27 137 100
Feb 17, 2016 $8.53 $8.53 $8.53 $8.53 279 100
Feb 16, 2016 $8.34 $8.34 $8.34 $8.34 283 100
Feb 12, 2016 $7.85 $7.85 $7.85 $7.85 177 000
Feb 11, 2016 $7.50 $7.50 $7.50 $7.50 144 200
Feb 10, 2016 $7.05 $7.05 $7.05 $7.05 149 700
Feb 09, 2016 $6.52 $6.52 $6.52 $6.52 608 500
Feb 08, 2016 $7.15 $7.15 $7.15 $7.15 246 500
Feb 05, 2016 $7.12 $7.12 $7.12 $7.12 125 800
Feb 04, 2016 $7.55 $7.55 $7.55 $7.55 314 900
Feb 03, 2016 $7.40 $7.40 $7.40 $7.40 301 800
Feb 02, 2016 $7.93 $7.93 $7.93 $7.93 385 400
Feb 01, 2016 $7.39 $7.39 $7.39 $7.39 326 100
Jan 29, 2016 $7.07 $7.07 $7.07 $7.07 238 100
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT